Global Alpha Emitters Strategic Business Report 2022: Featuring Actinium Pharmaceuticals, Alpha Tau Medical, Bayer and Fusion Pharma Among Others - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--Dec 7, 2022--

The "Alpha Emitters: Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.

The global market for Alpha Emitters estimated at US$684.5 Million in the year 2020, is projected to reach a revised size of US$2.5 Billion by 2027, growing at a CAGR of 20.6% over the analysis period 2020-2027.

Bone Metastasis, one of the segments analyzed in the report, is projected to record a 20.1% CAGR and reach US$888.5 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Ovarian Cancer segment is readjusted to a revised 21.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $203.1 Million, While China is Forecast to Grow at 19.9% CAGR

The Alpha Emitters market in the U.S. is estimated at US$203.1 Million in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$437.5 Million by the year 2027 trailing a CAGR of 19.9% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 18.4% and 17.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.3% CAGR.

Pancreatic Cancer Segment to Record 21.2% CAGR

In the global Pancreatic Cancer segment, USA, Canada, Japan, China and Europe will drive the 21.2% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$94.5 Million in the year 2020 will reach a projected size of US$357.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.

Select Competitors (Total 12 Featured) -

• Actinium Pharmaceuticals, Inc.
• Alpha Tau Medical
• Bayer AG
• Fusion Pharma
• IBA Group
• IBA Radiopharma Solutions
• Lantheus Medical Imaging, Inc.
• NTP Radiosotopes SOC Ltd.
• RadioMedix, Inc.
• Siemens Healthineers
• Telix Pharmaceuticals Ltd.
• Triad Isotopes, Inc.

What's New for 2022?

• Global competitiveness and key competitor percentage market shares
• Market presence across multiple geographies - Strong/Active/Niche/Trivial
• Online interactive peer-to-peer collaborative bespoke updates
• Access to digital archives and a Research Platform
• Complimentary updates for one year

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Alpha Emitters - Global Key Competitors Percentage Market Share in 2022 (E)
• Impact of Covid-19 and a Looming Global Recession
• Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/sjgsx1

View source version on businesswire.com:https://www.businesswire.com/news/home/20221207005424/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2022.